

Intravenous Immunoglobulin (IVIg) Market is entering a new age of innovation & productivity and growing at CAGR of 6.1%

The IVIG is considered to be the most effective treatment for hypogammaglobulinemia, CIDP, and immunodeficiency diseases.

PORTLAND, OR, UNITED STATES,
October 12, 2021 /EINPresswire.com/ --
UPDATE AVAILABLE ON-DEMAND
(Intravenous Immunoglobulin (IVIg)
Market to Set New Growth Cycle)

The IVIG products gained significant attention in the recent years due to their high efficacy in the treatment of immune diseases. Prevalence of

various antibody deficiency disorders such as common variable immune deficiency (CVID), specific antibody deficiency, and hypogammaglobulinemia, increase in IVIG indications, improved production & purification processes, growth in awareness towards antibody deficiency, and rare immune disorders among patient population drive the growth of the IVIG market.

The [Malaysia IVIG market](#) accounted for \$12,277 thousand in 2015, and is estimated to reach at \$18,649 thousand by 2022, registering a CAGR of 6.1% from 2016 to 2022. The scope of applications of IVIG has widened, as it is used to treat various neurological, hematological, dermatological, and immune deficiency disorders, with the help of improved clinical practices and advanced technologies.

Covid-19 Scenario:

- 1) The Covid-19 pandemic and followed by lockdown has affected several manufacturing industries.
- 2) The prolonged lockdown resulted in a disrupted supply chain and increased the prices of raw materials.
- 3) However, as the world has been recovering from the pandemic, the market is estimated to get



Malaysia Intravenous Immunoglobulin (IVIg)

back on track.

Download Free Report Sample @ <https://www.alliedmarketresearch.com/request-sample/2281>

However, high costs associated with the IVIG treatment; shortage of IVIG; and side effects of IVIG treatment such as headache, migraine, fever, nausea or vomiting, and cough hinder the market growth. IVIG products are widely used for the treatment of immunodeficiency disease, ITP, chronic lymphocytic leukemia (CLL), Kawasaki disease, and others. The untapped potential of Malaysia as an emerging market and development of cost-effective therapeutics through large-scale production act as opportunities to the market players in this region.

Hypogammaglobulinemia and CIDP held dominant market shares in 2015 due to the large patient population and unavailability of effective alternatives to IVIG treatment. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. On the basis of concentration, it is categorized into 5%, 10%, and others. By mode of delivery, it is bifurcated into intravenous, subcutaneous, and intramuscular mode of delivery. The intravenous mode of delivery segment held the largest revenue in 2015 and is anticipated to continue this trend during the forecast period. High bioavailability of immunoglobulins and rapid absorption rate offered by intravenous mode of delivery are the factors that supplement the growth of the intravenous mode of delivery IVIG market.

The Major key companies profiled Are:

Grifols S.A., Octapharma AG, Green Cross Corporation, Baxalta (Shire), Bio Products Laboratory Ltd., Biotest AG, CSL Behring, Omrix Biopharmaceuticals Ltd., Bayer Healthcare, and Baxter International Inc.

Inquire before buying @ <https://www.alliedmarketresearch.com/purchase-enquiry/2281>

Key Findings of the Malaysia IVIG Market:

- Hypogammaglobulinemia accounted for the largest revenue in 2015 owing to the lack of effective substitute treatment, and early adoption of IVIG
- Myasthenia gravis is anticipated grow at the fastest CARG of 9.1% in the forecast period.
- The intravenous mode of delivery was the highest revenue generating segment in 2015 and is anticipated to continue this trend during the forecast period.
- 10% concentration held the highest market share in 2015. This trend is likely to continue throughout the forecast period.

Trending Reports in Healthcare Industry (Book Now with 10% Discount):

[Vertebroplasty and Kyphoplasty Market Analysis, Industry Forecast, 2030](#)

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Analytics LLP
+1 503-894-6022
[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/553650371>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.